Literature DB >> 12050371

Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge.

Marian E Major1, Kathleen Mihalik, Montserrat Puig, Barbara Rehermann, Michelina Nascimbeni, Charles M Rice, Stephen M Feinstone.   

Abstract

Responses in three chimpanzees were compared following challenge with a clonal hepatitis C virus (HCV) contained in plasma from an animal that had received infectious RNA transcripts. Two of the chimpanzees (Ch1552 and ChX0186) had recovered from a previous infection with HCV, while the third (Ch1605) was a naïve animal. All animals were challenged by reverse titration with decreasing dilutions of plasma and became serum RNA positive following challenge. Ch1605 displayed a typical disease profile for a chimpanzee. We observed increasing levels of serum RNA from week 1 postinoculation (p.i.), reaching a peak of 10(6) copies/ml at week 9 p.i., and alanine aminotransferase (ALT) elevations and seroconversion to HCV antibodies at week 10 p.i. In contrast, both Ch1552 and ChX0186 exhibited much shorter periods of viremia (4 weeks), low serum RNA levels (peak, 10(3) copies/ml), and minimal ALT elevations. A comparison of intrahepatic cytokine levels in Ch1552 and Ch1605 showed greater and earlier gamma interferon (IFN-gamma) and tumor necrosis factor alpha responses in the previously infected animal, responses that were 30-fold greater than baseline responses at week 4 p.i. for IFN-gamma in Ch1552 compared to 12-fold in Ch1605 at week 10 p.i. These data indicate (i) that clonal HCV generated from an infectious RNA transcript will lead to a typical HCV infection in naïve chimpanzees, (ii) that there are memory immune responses in recovered chimpanzees that control HCV infection upon rechallenge, and (iii) that these responses seem to be T-cell mediated, as none of the animals had detectable antibody against the HCV envelope glycoproteins. These observations have encouraging implications for the development of a vaccine for HCV.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12050371      PMCID: PMC136282          DOI: 10.1128/jvi.76.13.6586-6595.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

1.  Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA.

Authors:  A A Kolykhalov; E V Agapov; K J Blight; K Mihalik; S M Feinstone; C M Rice
Journal:  Science       Date:  1997-07-25       Impact factor: 47.728

2.  Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection.

Authors:  H M Diepolder; J T Gerlach; R Zachoval; R M Hoffmann; M C Jung; E A Wierenga; S Scholz; T Santantonio; M Houghton; S Southwood; A Sette; G R Pape
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

3.  Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy.

Authors:  B Robertson; G Myers; C Howard; T Brettin; J Bukh; B Gaschen; T Gojobori; G Maertens; M Mizokami; O Nainan; S Netesov; K Nishioka; T Shin i; P Simmonds; D Smith; L Stuyver; A Weiner
Journal:  Arch Virol       Date:  1998       Impact factor: 2.574

4.  Structure of the 3' terminus of the hepatitis C virus genome.

Authors:  T Tanaka; N Kato; M J Cho; K Sugiyama; K Shimotohno
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

5.  Comparative features of hepatitis C virus infection in humans and chimpanzees.

Authors:  C M Walker
Journal:  Springer Semin Immunopathol       Date:  1997

6.  Identification of a highly conserved sequence element at the 3' terminus of hepatitis C virus genome RNA.

Authors:  A A Kolykhalov; S M Feinstone; C M Rice
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

7.  Vaccination of chimpanzees against infection by the hepatitis C virus.

Authors:  Q L Choo; G Kuo; R Ralston; A Weiner; D Chien; G Van Nest; J Han; K Berger; K Thudium; C Kuo
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

8.  Effect of immune globulin on the prevention of experimental hepatitis C virus infection.

Authors:  K Krawczynski; M J Alter; D L Tankersley; M Beach; B H Robertson; S Lambert; G Kuo; J E Spelbring; E Meeks; S Sinha; D A Carson
Journal:  J Infect Dis       Date:  1996-04       Impact factor: 5.226

9.  Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization.

Authors:  P Farci; H J Alter; D C Wong; R H Miller; S Govindarajan; R Engle; M Shapiro; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-02       Impact factor: 11.205

10.  Analysis of hepatitis C virus-inoculated chimpanzees reveals unexpected clinical profiles.

Authors:  S E Bassett; K M Brasky; R E Lanford
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

View more
  62 in total

1.  Exposure to low infective doses of HCV induces cellular immune responses without consistently detectable viremia or seroconversion in chimpanzees.

Authors:  Mohamed Tarek Shata; Nancy Tricoche; Marion Perkus; Darley Tom; Betsy Brotman; Patricia McCormack; Wolfram Pfahler; Dong-Hun Lee; Leslie H Tobler; Michael Busch; Alfred M Prince
Journal:  Virology       Date:  2003-09-30       Impact factor: 3.616

2.  Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins.

Authors:  Harel Dahari; Stephen M Feinstone; Marian E Major
Journal:  Gastroenterology       Date:  2010-06-02       Impact factor: 22.682

3.  A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques.

Authors:  Stefania Capone; Annalisa Meola; Bruno Bruni Ercole; Alessandra Vitelli; Monica Pezzanera; Lionello Ruggeri; Mary Ellen Davies; Rosalba Tafi; Claudia Santini; Alessandra Luzzago; Tong-Ming Fu; Andrew Bett; Stefano Colloca; Riccardo Cortese; Alfredo Nicosia; Antonella Folgori
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

Review 4.  Adaptive immunity to the hepatitis C virus.

Authors:  Christopher M Walker
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

5.  Hepatitis C virus clearance correlates with HLA-DR expression on proliferating CD8+ T cells in immune-primed chimpanzees.

Authors:  Iryna Zubkova; Hongying Duan; Frances Wells; Howard Mostowski; Esther Chang; Kathleen Pirollo; Kris Krawczynski; Robert Lanford; Marian Major
Journal:  Hepatology       Date:  2014-01-28       Impact factor: 17.425

Review 6.  T-bet-expressing B cells during HIV and HCV infections.

Authors:  James J Knox; David E Kaplan; Michael R Betts
Journal:  Cell Immunol       Date:  2017-07-11       Impact factor: 4.868

7.  Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees.

Authors:  Heidi Barth; Jolanta Rybczynska; Romuald Patient; Youkyung Choi; Ronda K Sapp; Thomas F Baumert; Kris Krawczynski; T Jake Liang
Journal:  Hepatology       Date:  2011-08-11       Impact factor: 17.425

Review 8.  Neutralizing antibodies in hepatitis C virus infection.

Authors:  Mirjam-B Zeisel; Samira Fafi-Kremer; Isabel Fofana; Heidi Barth; Francoise Stoll-Keller; Michel Doffoel; Thomas-F Baumert
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

Review 9.  Host and viral factors contributing to CD8+ T cell failure in hepatitis C virus infection.

Authors:  Christoph Neumann-Haefelin; Hans-Christian Spangenberg; Hubert-E Blum; Robert Thimme
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

Review 10.  Progress on new vaccine strategies against chronic viral infections.

Authors:  Jay A Berzofsky; Jeffrey D Ahlers; John Janik; John Morris; SangKon Oh; Masaki Terabe; Igor M Belyakov
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.